Journal of Nutrition EB Program 2010 Early Registration

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jonkers, I. J. A. M.
Right arrow Articles by Stellaard, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jonkers, I. J. A. M.
Right arrow Articles by Stellaard, F.
© 2006 American Society for Nutrition J. Nutr. 136:987-991, April 2006

Nutrition and Disease

Fish Oil Increases Bile Acid Synthesis in Male Patients with Hypertriglyceridemia1

Iris J. A. M. Jonkers*, Augustinus H. M. Smelt*,2, Hans M. G. Princen{dagger}, Folkert Kuipers**, Johannes A. Romijn{ddagger}, Renze Boverhof**, Ad A. M. Masclee{dagger}{dagger} and Frans Stellaard**

Departments of * General Internal Medicine, {dagger}{dagger} Gastroenterology, and {ddagger} Endocrinology of the Leiden University Medical Center, Leiden, The Nettherlands; {dagger} Gaubius Laboratory, TNO-PG, Leiden, The Nettherlands; and ** Center for Liver, Intestinal and Metabolic Diseases, Academic Hospital Groningen, Groningen, The Netherlands

2 To whom correspondence should be addressed. E-mail: a.h.m.smelt{at}lumc.nl.


   ABSTRACT
TOP
 ABSTRACT
SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 LITERATURE CITED
 
Fibrates are drugs of choice in patients with hypertriglyceridemia (HTG), but may increase the risk for gallstones by decreasing bile acid synthesis. Fish oil might be a therapeutic alternative, but its effect on bile acid metabolism in humans is unknown. We compared the effects of triglyceride-lowering therapy by fish oil or bezafibrate on cholesterol synthesis and bile acid metabolism in HTG. Cholesterol synthesis, bile acid pool sizes, and synthesis rates were compared between 9 male HTG patients and 10 normolipidemic controls matched for age, sex, and BMI. Effects of bezafibrate or fish oil were studied only in HTG patients in a randomized crossover trial. Patients had 14-fold higher serum triglyceride concentrations and greater cholesterol synthesis, as indicated by a 107% higher ratio of serum lathosterol to cholesterol (P < 0.01) than controls. The groups did not differ in bile acid metabolism. Both bezafibrate and fish oil reduced serum TG concentration (–68 and –51% vs. baseline, respectively). Compared with baseline, bezafibrate therapy was associated with reduced cholesterol synthesis (–25%, P = 0.009) without changes in bile acid synthesis rate and pool size. In contrast, fish oil increased bile acid synthesis (+31% vs. baseline, P = 0.07 and +53% vs. bezafibrate, P = 0.02) and altered bile acid distribution, as reflected by an increased ratio of the cholic acid (CA) synthesis rate to the chenodeoxycholic acid (CDCA) synthesis rate (+35% vs baseline, P = 0.05 and + 32% vs bezafibrate, P = 0.07) without effects on bile acid pool size or cholesterol synthesis. In conclusion, cholesterol synthesis is greater in HTG patients than in controls, whereas bile acid synthesis does not differ. Bezafibrate and fish oil have similar triglyceride-lowering capacities, but distinct effects on cholesterol synthesis. Bile acid synthesis is increased by fish oil, but not by bezafibrate therapy.

KEY WORDS: • triglycerides • bezafibrate • fish oil • bile acid synthesis • hypertriglyceridemia

Hypertriglyceridemia (HTG)3 is associated with cardiovascular disease (1), pancreatitis (2) and cholesterol gallstone formation (3,4). The disorder is characterised by elevated plasma TG concentrations, mainly in very-low-density-lipoprotein (VLDL), low levels of HDL-cholesterol, and insulin resistance. Several studies have addressed cholesterol (5–8), and bile acid metabolism (6,9–14) in HTG, mainly in relation to the increased risk for gallstone disease. In general, these studies revealed the presence of bile supersaturated with cholesterol (12,15) as well as increased cholesterol and bile acid synthesis in HTG (3,7–12).

Fibrates are commonly used in the treatment of HTG patients in order to prevent cardiovascular disease by lowering TG levels (16). However, fibrates may increase the risk for cholelithiasis (17–19) by increasing biliary cholesterol saturation (20) through increased biliary cholesterol secretion and inhibition of bile acid synthesis (21,22). Fish oil, that also effectively lowers plasma TG levels (23), has been shown to have profound favorable effects on cardiovascular risk (24) and is a therapeutic alternative for fibrates in HTG patients (25). However, the effects of fish oil on cholesterol synthesis and bile acid metabolism in humans are unknown. Therefore the aim of this study was to evaluate the effects of hypertriglyceridemia (HTG) on cholesterol synthesis and bile acid metabolism as well as to compare triglyceride-lowering therapy by bezafibrate and fish oil on cholesterol synthesis and bile acid metabolism in patients with HTG.


   SUBJECTS AND METHODS
TOP
 ABSTRACT
 SUBJECTS AND METHODS
RESULTS
 DISCUSSION
 LITERATURE CITED
 
    Subjects and study design. This study is part of a larger study investigating the effects of HTG and lipid lowering therapy on biliary lipid secretion and gallbladder motility. The subjects and study design as well as specific analytical techniques have been published in detail (25). In short, the study population consisted of 9 unrelated male patients with endogenous HTG and 10 normolipidemic, age-, sex- and BMI-matched healthy control subjects. The diagnosis endogenous HTG was based on the mean of two fasting blood samples obtained after a step 1 diet of the NCEP (26) for at least 8 wk. The presence of asymptomatic gallstones or sludge was excluded by ultrasound. If the patients used lipid-lowering therapy before the study-onset, this was stopped for at least 6 wk prior to the study entry. None of the participants took any medication known to affect cholesterol or bile acid metabolism.

The study started with the assessment of baseline values in both controls and HTG patients: fasting blood samples were taken for determination of lathosterol and cholesterol concentrations at visit 1. At visit 2 (one wk later) fasting blood samples were taken for the assessment of serum lipids and bile acids, after which measurement of bile acid kinetics was started as detailed below. For this purpose, during 5 consecutive days postprandial morning and evening blood samples were taken. Hereafter, HTG patients were randomized to receive in a cross-over fashion either bezafibrate (Bezalip retard®, Hoffmann-La Roche Ltd, Basel, Switzerland), 400 mg once daily or fish oil 5 g/day (Triomar®, Lube, Hadsund, Denmark; containing 3.6 g (n–3) fatty acids (eiconsapentaenoic acid, C20:5(n–3) 1.9 g and docosahexaenoic acid C22:6(n–3) 1.1 g)) for 7 wk. These two treatment periods were separated by a 6-wk washout period without lipid-lowering medication. At the onset and in week 7 of the treatment periods fasting blood samples were obtained. Serum lipids and cholesterol synthesis were investigated in week 6, whereas in week 7 of each treatment period bile acids synthesis was determined. Informed consent was obtained from each participant and the protocol was approved by the Medical Ethics Committee of the Leiden University Medical Center.

    Sample collection and lipid analysis. Blood sampling and serum lipid, glucose, insulin and total bile acid analyses were performed as described previously (25,27). Insulin resistance was assessed using the homeostasis model approximation (HOMA) by the following formula: insulin resistance = insulin/(22.5e-lnglucose).

    Cholesterol synthesis. The serum lathosterol to cholesterol ratio was used as indicator of cholesterol synthesis (28). Total (free and esterified) serum cholesterol was measured colorimetrically, whereas total lathosterol was assayed by gas-liquid chromatography (28).

    Bile acid synthesis and pool sizes. Participants had a standardized breakfast (3263 kJ, 50 g fat, 42 g protein, 38 g carbohydrates) at the research department at 0830 AM. At 1030 AM a blood sample was taken to determine the isotope distribution of endogenous bile acids. Thereafter, 50 mg [2,2,4,4-2H4] Cholic Acid (CA) and 50 mg [2,2,4,4-2H4] Chenodeoxycholic Acid (CDCA) (CDN Isotopes, Ponte-Claire, Quebec, Canada) dissolved in 200 mL 0.5% NaHCO3 were taken. On the next 5 d blood samples were taken 2 h after both breakfast and diner.

Deuterium enrichments for both CA and CDCA were measured simultaneously in 50 µL plasma samples by gas chromatography mass spectrometry (GC/MS), selected ion-monitoring (29) applying negative ion chemical ionization (NICI). Some modifications were necessary to overcome problems due to the high triglyceride concentration in plasma of the patients. This affected the stability in recovery, chromatographic peak shape and retention time as well as the stability in mass spectrometry performance. Therefore, the protocol was modified as follows. The sample obtained after enzymatic deconjugation (29) of 200 µL plasma was extracted twice with 4 mL hexane to remove neutral lipids. Thereafter the residual sample was acidified and extracted with diethylether to continue the original protocol. The gas chromatography separation was slightly modified using a 2 m x 0.25 mm (0.25µm film thickness) OV1701 column (CPSil 19CB, Chrompack BV, Middelburg, The Netherlands) as a guard column between the injector and the 15m x 0.25 mm (0.25µm film thickness) DB5ms (J&W Scientific, Folsom, CA, U.S.A.) analytical column as described. These modifications improved the long-time stability of the measurements. The selected ion monitoring parameters were extended for the measurement of isotope enrichment for chenodeoxycholic acid PFB TMS derivative: m/z 535 and 539.

    Calculations. From the isotope enrichment the pool size, the fractional turnover rate and the synthesis rate were calculated for CA and CDCA (30). From the calculated CA and CDCA pool sizes and the fraction of deoxycholic acid (DCA) in the biliary bile acid profile, the DCA pool size was determined. The total bile acid synthesis was calculated as the sum of the CA synthesis rate and CDCA synthesis rate.

    Data and statistical analysis. Results are expressed as means ± SEM. Differences between the HTG patients and controls were tested using the Mann-Whitney-U-test. Differences between HTG patients at baseline and after bezafibrate or fish oil therapy were evaluated by ANOVA and the post-hoc LSD test. Linear regression analysis was performed to identify whether insulin, glucose or insulin resistance as group-associated confounders contributed to the results. P-values ≤ 0.05 were considered significant.


   RESULTS
TOP
 ABSTRACT
 SUBJECTS AND METHODS
 RESULTS
DISCUSSION
 LITERATURE CITED
 
    Baseline characteristics. Age, sex, BMI and fasting serum glucose levels did not differ between HTG patients and controls. In contrast, fasting insulin levels (+35%, P = 0.059) as well as the HOMA-index as a measure of insulin resistance (+45%, P = 0.034) were higher in HTG patients than in controls. By definition, HTG patients had higher serum total TG and VLDL-TG concentrations than controls, whereas the other lipoprotein fractions also differed from those in controls (Table 1).


View this table:
[in this window]
[in a new window]
  		TABLE 1 Characteristics and serum biochemistry of male controls and HTG patients at baseline and after 7 wk of bezafibrate and fish oil therapy1

 
    Effects of fish oil and bezafibrate on serum biochemistry in HTG patients. Serum lipid levels in HTG patients did not differ between the first "baseline" determination and measurements before the start of the bezafibrate and fish oil treatment periods. Therefore, only serum lipid levels at the end of these periods were compared (Table 1). Both fish oil and bezafibrate decreased total serum TG, VLDL-TG, total cholesterol and VLDL cholesterol concentrations, whereas low-density-lipoprotein (LDL)- and HDL-cholesterol concentrations increased (Table 1). Lipid-lowering effects did not differ between fish oil and bezafibrate, except for the VLDL-TG concentration, which was 35% lower after bezafibrate than after fish oil therapy (P = 0.04).

Bezafibrate therapy did not affect fasting glucose, fasting insulin levels and the degree of insulin resistance (Table 1). In contrast, fish oil significantly increased all three compared to both baseline (+7%, P = 0.023; +36%, P = 0.007 and +44%, P = 0.01, respectively) and to bezafibrate therapy (+7%, P = 0.02, +39%, P = 0.006 and +49%, P = 0.007, respectively, Table 1).

    Cholesterol synthesis. Cholesterol synthesis was higher in HTG patients than in age-, sex- and BMI-matched controls as deduced from the 107% higher ratio of serum lathosterol to cholesterol (Fig. 1, P = 0.008). Fish oil did not affect cholesterol synthesis in HTG patients, whereas bezafibrate therapy decreased this ratio compared to baseline (–25%, P = 0.009) as well as to after fish oil therapy (–22%, P = 0.024, Fig. 1). Regression analysis showed that serum glucose and insulin concentrations and insulin resistance did not contribute to the increased cholesterol synthesis in HTG patients (all P > 0.23).


Figure 1
View larger version (11K):
[in this window]
[in a new window]
  		FIGURE 1  The ratio of serum lathosterol to cholesterol, a measure of cholesterol synthesis, in male controls (n = 10) and male HTG patients (n = 9) at baseline, and in HTG patients after 7 wk of bezafibrate and fish oil therapy. Values are means ± SEM. *Different from controls, P ≤ 0.05; ** Different from HTG patients at baseline P ≤ 0.05; {dagger} Different from HTG patients during bezafibrate treatment, P ≤ 0.05.

 
    Bile acid synthesis and pool sizes. The biliary bile acid compositions (CA, CDCA and DCA) were similar in HTG patients and were not affected by fish oil or bezafibrate therapy (data not shown). Bile acid synthesis rates, fractional turnover rates and pool sizes did not differ between HTG patients and controls (Table 2.). Fish oil tended to increase CA- and total bile acid synthesis rates (+45%, P = 0.071 and +31%, P = 0.079, respectively) as well as CA fractional turnover rate (+20%), without effects on CDCA synthesis rate, and fractional turnover rate, or individual and total pool sizes. As a consequence, the ratio of the CA synthesis rate to the CDCA synthesis rate was 35% greater after fish oil therapy compared to baseline (P = 0.05, Table 2). Bezafibrate therapy did not affect CA-, CDCA-, DCA- and total bile acid pool sizes, and CA-, CDCA-, and total bile acid synthesis rates, or fractional turnover rates in HTG patients.


View this table:
[in this window]
[in a new window]
  		TABLE 2 Pool sizes, fractional turnover rates and synthesis rates of individual and total bile acids in male controls and HTG patients at baseline, and after 7 wks of bezafibrate or fish oil therapy1

 
In comparison to bezafibrate therapy, fish oil resulted in higher CA (+68%, P = 0.02), CDCA (+28%, P = 0.05), and total bile acid synthesis rates (+53%, P = 0.02) and a 32% greater ratio of the CA synthesis rate to the CDCA synthesis rate (P = 0.07, Table 2).


   DISCUSSION
TOP
 ABSTRACT
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
LITERATURE CITED
 
This study shows that HTG patients have increased cholesterol synthesis, whereas their bile acid metabolism did not differ from age-, sex- and BMI-matched controls. Furthermore, we observed that fish oil and bezafibrate therapy exerted similar lipid-lowering effects in HTG patients, but had distinctly different effects on cholesterol and bile acid metabolism. Fish oil increased bile acid synthesis, specifically CA synthesis, without effects on bile acid pool size or cholesterol synthesis. Bezafibrate, in contrast, significantly decreased cholesterol synthesis, while it tended to decrease bile acid synthesis as well.

In line with earlier studies (5–8), HTG patients showed an increased cholesterol synthesis in comparison to controls even after correction for BMI (intrinsically by BMI-matching) and insulin resistance (by regression analysis). At first sight these data conflict the study of Duane et al. demonstrating that cholesterol synthesis did not differ from BMI-matched controls in comparison with patients with FHTG (31). However, it should be noted that this study focused on FHTG, a genetically distinct entity of HTG. Furthermore, one outlier in the control group of that study markedly influenced the results, and exclusion of this outlier revealed a tendency to increased cholesterol synthesis in FHTG as well.

Bile acid synthesis, fractional turnover rates and bile acid pool sizes did not significantly differ in HTG patients compared to those of controls, disputing earlier studies, demonstrating increased bile acid FTR (10,12) and increased bile acid synthesis (6,9–12,14) in HTG patients. However, in these studies there were large inter-individual differences with regard to abnormalities in bile acid metabolism (14) Moreover, in those studies HTG patients had higher BMIs than controls and obesity itself is associated with increased bile acid synthesis (32,33), whereas weight reduction is associated with reduced bile acid synthesis in HTG (34). The lack of significant differences in our study might be explained by the fact that HTG patients were compared to BMI-matched controls. In addition, it could be that we did not observe differences in bile acid metabolism in HTG patients due to the small-sample size of our study population. However, we assume that large differences would have been noted in our study.

Earlier studies showed reductions in both cholesterol- and bile acid synthesis upon fibrate therapy in both humans (21,22) and mice (35). These effects may be explained by fibrates-induced PPAR{alpha}-mediated down-regulation of cholesterol 7{alpha}-hydroxylase and sterol 27-hydroxylase gene expression (22), whereas fibrates have been shown to diminish cholesterol biosynthesis through inhibition of HMG CoA- synthase as well as HMG CoA reductase (36). In our study we did not observe a decrease in bile acid synthesis during bezafibrate therapy, which may be due to the small sample size of the study.

The hypotriglyceridemic effect of fish oil is well known (23) and confirmed in our study. In contrast, the effect of fish oil on insulin-resistance is less cIear: some studies observed no effect (37), whereas others, similar to our observation documented an increase in insulin resistance upon fish oil (38).

This is the first study describing the effects of fish oil on bile acid synthesis in humans, whereas only scarce data are available in animals. In rats, fish oil has been shown to increase cholesterol secretion into bile (39,40), and to increase bile acid pool size and synthesis rate (41), although others found no effect on bile acid synthesis in rats (39) or hamsters (42). Furthermore, fish oil increased cholesterol 7{alpha}-hydroxylase gene expression in mice (43). These differences in bile acid metabolism may be due to the animal model used (44). In the present study fish oil increased bile acid synthesis, specifically CA synthesis in comparison to both baseline and bezafibrate. This observation is of interest, since over the past years several groups suggested a reciprocal relationship between TG synthesis and bile acid synthesis: upon treatment with bile acid-binding resins serum TG concentration increased (45,46) whereas upon treatment with CDCA TG levels decreased (47,48). To the best of our knowledge this is the first study describing divergent effects on serum triglyceride levels and bile acid synthesis, suggesting that the coupling between bile acid synthesis and triglyceride synthesis may not be as direct as previously suggested and may involve alternative mechanisms. The mechanism behind the hypotriglyceridemic action of fish oil is unknown. Whereas the hypotriglyceridemic effect of fibrates is attributed to activation of PPAR{alpha}, experiments with PPAR{alpha} knock-out mice (49) showed that the triglyceride lowering effect of fish oil was not abolished, indicating that this action of fish oil is not mediated by PPAR{alpha}. Recently, it was reported that fish oil may decrease hepatic VLDL production by stimulating apoB degradation via post-ER-pre-secretory proteolysis or PERPP (50). Further studies are required to elucidate the underlying mechanism of triglyceride-lowering in relation to bile acid synthesis upon fish oil treatment.

In conclusion, the current study demonstrates that in HTG patients cholesterol synthesis was increased compared to BMI matched controls, while bile acid pool size and synthesis were similar in both groups. In HTG patients however, bezafibrate significantly reduced cholesterol synthesis, without a significant effect on bile acid synthesis. Fish oil exerted similar TG-lowering capacities, increased bile acid synthesis, without affecting cholesterol synthesis.


   FOOTNOTES
 
1 Supported by the Gastrostart Foundation. Back

3 Abbreviations used: CA, cholic acid; CDCA, chenodeoxycholic acid; CVD, cardiovascular disease; CYP7A1, cholesterol 7{alpha}-hydroxylase; DCA, deoxycholic acid; FTR, fractional turnover rate; HDL-C, HDL cholesterol; HOMA, homeostasis model approximation; HTG, hypertriglyceridemia; PPAR, peroxisome proliferator-activated receptor. Back

Manuscript received 3 November 2005. Initial review completed 29 November 2005. Revision accepted 1 January 2006.


   LITERATURE CITED
TOP
 ABSTRACT
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 LITERATURE CITED
 

1. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–9.[Medline]

2. Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am. 1990;19:783–91.[Medline]

3. Einarsson K, Hellstrom K, Kallner M. Gallbladder disease in hyperlipoproteinaemia. Lancet. 1975;1:484–7.[Medline]

4. Ahlberg J, Angelin B, Einarsson K, Hellstrom K, Leijd B. Prevalence of gallbladder disease in hyperlipoproteinemia. Dig Dis Sci. 1979;24:459–64.[Medline]

5. Asplund-Carlson A, Lund E, Björkhem I, Carlson LA. Studies in hypertriglyceridaemia VI: serum lathosterol concentration is raised in hypertriglyceridaemic non-diabetic males with hyperinsulinaemia. J Intern Med. 1999;245:247–52.[Medline]

6. Shoda J, Miyamoto J, Kano M, Ikegami I, Matsuzaki Y, Tanaka N, Osuga T, Miyazaki H. Simultaneous determination of plasma mevalonate and 7-hydroxy-4-cholesten-3-one levels in hyperlipoproteinemia: Convenient indices for estimating hepatic defects of cholesterol and bile acid syntheses and biliary cholesterol supersaturation. Hepatology. 1997;25:18–26.[Medline]

7. Ahlberg J, Angelin B, Bjorkhem I, Einarsson K, Leijd B. Hepatic cholesterol metabolism in normo- and hyperlipidemic patients with cholesterol gallstones. J Lipid Res. 1979;20:107–15.[Abstract]

8. Beil U, Grundy SM, Crouse JR, Zech L. Triglyceride and cholesterol metabolism in primary hypertriglyceridemia. Arteriosclerosis. 1982;2:44–57.[Abstract/Free Full Text]

9. Einarsson K, Hellstrom K, Kallner M. Bile acid kinetics in relation to sex, serum lipids, body weights and gallbladder disease in patients with various types of hyperlipoproteinemia. J Clin Invest. 1974;54:1301–11.[Medline]

10. Angelin B, Hershon KS, Brunzell JD. Bile acid metabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia. Proc Natl Acad Sci USA. 1987;84:5434–8.[Abstract/Free Full Text]

11. Angelin B, Einarrson K. Hellstrom, K. & Leijd, B. Bile acid kinetics in relation to endogenous triglyceride metabolism in various types of hyperlipoproteinemia. J Lipid Res. 1978;19:1004–16.[Abstract]

12. Duane WC. Abnormal bile acid absorption in familial hypertriglyceridemia. J Lipid Res. 1995;36:96–107.[Abstract]

13. Nestel PJ, Hunter JD. Differences in bile acid excretion in subjects with hypercholesterolaemia, hypertrglyceridaemia and overweight. Aust N Z J Med. 1974;4:497–501.[Medline]

14. Duane WC, Hartich LA, Bartman AE, Ho SB. Diminished gene expression of ileal apical sodium bile acid transporter explains impaired absorption of bile acid in patients with hypertriglyceridemia. J Lipid Res. 2000;41:1384–9.[Abstract/Free Full Text]

15. Ahlberg J, Angelin B, Einarsson K, Hellstrom K, Leijd B. Biliary lipid composition in normo- and hyperlipoproteinemia. Gastroenterology. 1980;79:90–4.[Medline]

16. Fruchart JC, Brewer HBJ, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol. 1998;81:912–7.[Medline]

17. Cooper J, Geizerova H, Oliver MF. Clofibrate and gallstones. Lancet. 1975;1:1083.[Medline]

18. Bateson MC, Maclean D, Ross PE, Bouchier IA. Clofibrate therapy and gallstone induction. Am J Dig Dis. 1978;23:623–8.[Medline]

19. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–381.[Abstract/Free Full Text]

20. Palmer RH. Effects of fibric acid derivatives on biliary lipid composition. Am J Med. 1987;83:37–43.[Medline]

21. Bertolotti M, Concari M. Loria, P., Abate, N., Pinetti, A., Guicciardi, M. E. & Carulli, N. Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rate of cholesterol 7 alpha-hydroxylation in humans. Arterioscler Thromb Vasc Biol. 1995;15:1064–9.[Abstract/Free Full Text]

22. Stahlberg D, Reihner E, Rudling M, Bergland L, Einarsson K, Angelin B. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 alpha-hydroxylase. Hepatology. 1995;21:1025–30.[Medline]

23. Nestel PJ. Fish oil and cardiovascular disease: lipids and arterial function. Am J Clin Nutr. 2000;71: suppl:228S–231S.[Abstract/Free Full Text]

24. Bucher HC, Heugstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112:298–304.[Medline]

25. Jonkers IJ, Smelt AH, Ledeboer M, Hollum ME, Biemond I, Kuipers F, Stellaard F, Boverhof R, Meinders AE, et al. Gallbladder dysmotility: a risk factor for gallstone formation in hypertriglyceridemia. Reversal upon triglyceride-lowering therapy by both bezafibrate and fish-oil. Gut. 2003;52:109–15.[Abstract/Free Full Text]

26. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on DetectionEvaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015–23.[Abstract/Free Full Text]

27. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med. 2002;112:275–80.[Medline]

28. Kempen HJM, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988;29:1149–55.[Abstract]

29. Hulzebos CV, Renfurm L, Bandsma RH, Verkade HJ, Boer T, Boverhof R, Tanaka H, Mierau I, Sauer PJ, et al. Measurement of parameters of cholic acid kinetics in plasma using a microscalestable isotope dilution technique: application to rodents and humans. J Lipid Res. 2001;42:1923–9.[Abstract/Free Full Text]

30. Berr F, Stellaard F, Pratschke E, Paumgartner G. Effects of cholecystectomy on the kinetics of primary and secondary bile acids. J Clin Invest. 1989;83:1541–50.[Medline]

31. Duane WC. Cholesterol metabolism in familial hypertriglyceridemia: effects of obesity versus triglyceride levels. J Lab Clin Med. 1997;130:635–42.[Medline]

32. Stahlberg D, Rudling M, Angelin B, Bjorkhem I, Forsell P, Nilsell K, Einarsson K. Hepatic cholesterol metabolism in human obesity. Hepatology. 1997;25:1447–50.[Medline]

33. Miettinen TA. Cholesterol production in obesity. Circulation. 1971;44:842–50.[Abstract/Free Full Text]

34. Leijd B. The effect of weight reduction on biliary lipid metabolism in patients with hyperlipoproteinemia type IV. Metabolism. 1981;30:1185–9.[Medline]

35. Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7 alpha-hydroxylase expression. Arterioscler Thromb Vasc Biol. 2001;21:1840–5.[Abstract/Free Full Text]

36. Guo Q, Wang PR, Milot DP, Ippolito MC, Hernandez M, Burton CA, Wright SD, Chao YS. Regulation of lipid metabolism and gene expression by fenofibrate in hamsters. Biochim Biophys Acta. 2001;1533:220–32.[Medline]

37. Sirtori CR, Paoletti R, Mancini M, Crepaldi G, Manzato E, Rivellese A, Pamparana F, Stragliotto E. N-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study. Am J Clin Nutr. 1997;65:1874–81.[Abstract/Free Full Text]

38. Dunstan DW, Mori TA, Puddey IB, Beilin LJ, Burke V, Morton AR, Stanton KG. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. A randomized controlled study. Diabetes Care. 1997;20:913–21.[Abstract]

39. Bravo E, Cantafora A, DeLuca V, Tripodi M, Avella M, Botham KM. The mechanism underlying the hypocholesterolemic effect of chronic fish oil feeding in rats is not due to increased excretion of dietary cholesterol. Atherosclerosis. 1998;139:253–263.[Medline]

40. Smit MJ, Verkade HJ, Havinga R, Vonk RJ, Scherphoff GL. In 't Veld, G. & Kuipers, F. Dietary fish oil potentiates bile acid-induced cholesterol secretion into bile in rats. J Lipid Res. 1994;35:301–10.[Abstract]

41. Smit MJ, Temmerman AM, Wolters H, Kuipers F, Beynen AC, Vonk RJJ. Dietary fish oil-induced changes in intrahepatic cholesterol transport and bile acid synthesis in rats. J Clin Invest. 1991;88:943–51.[Medline]

42. Berr F, Goetz A, Schreiber E, Paumgartner G. Effect of dietary n-3 versus n-6 polyunsaturated fatty acids on hepatic excretion of cholesterol in the hamster. J Lipid Res. 1993;34:1275–84.[Abstract]

43. Cheema SK. Dietary fats modulate the regulatory potential of dietary cholesterol on cholesterol 7 alpha-hydroxylase gene expression. J Lipid Res. 1997;38:315–23.[Abstract]

44. Horton JD, Cuthbert JA, Spady DK. Regulation of hepatic 7{alpha}-hydroxylase expression and response to dietary cholesterol in the rat and hamster. J Biol Chem. 1995;270:5381–7.[Abstract/Free Full Text]

45. Adler RD, Bennion LJ, Duane WC, Grundy SM. Effects of low dose chenodeoxycholic acid feeding on biliary lipid metabolism. Gastroenterology. 1975;68:326–34.[Medline]

46. Einarsson K, Ericsson S, Ewerth S, Reihner E, Rudling M, Stahlberg D, Angelin B. Bile acid sequestrants: mechanism of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol. 1991;40: suppl1:S53–8.[Medline]

47. Miller NE, Nestel PJ. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet. 1974;2:929–31.[Medline]

48. Angelin B, Einarrson K, Hellstrom K, Leijd B. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. J Lipid Res. 1978;19:1017–24.[Abstract]

49. Dallongeville J, Bauge E, Tailleux A, Peters JM, Gonzales FJ. Fruchart. j. C. & Staels, B. Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil. J Biol Chem. 2001;276:4634–9.[Abstract/Free Full Text]

50. Fisher EA, Pan M, Chen X, Wu X, Wang H, Jamil H, Sparks JD, Williams KJ. The triple threat to nascent apolipoprotein B. J Biol Chem. 2001;276:27855–63.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
 J. Nutr.Home page
V. Saraswathi, J. D. Morrow, and A. H. Hasty
Dietary Fish Oil Exerts Hypolipidemic Effects in Lean and Insulin Sensitizing Effects in Obese LDLR-/- Mice
J. Nutr., December 1, 2009; 139(12): 2380 - 2386.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. Manlhiot, P. Larsson, R. C. Gurofsky, R. W. Smith, C. Fillingham, N. A. Clarizia, N. Chahal, J. T. Clarke, and B. W. McCrindle
Spectrum and Management of Hypertriglyceridemia Among Children in Clinical Practice
Pediatrics, February 1, 2009; 123(2): 458 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Physiol Rev, January 1, 2009; 89(1): 147 - 191.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jonkers, I. J. A. M.
Right arrow Articles by Stellaard, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jonkers, I. J. A. M.
Right arrow Articles by Stellaard, F.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Copyright © 2006 by American Society for Nutrition